- Safety of Obesity Drugs

Obesity ◽  
2012 ◽  
pp. 354-407
Keyword(s):  
Obesity Drugs

Obesity Drugs Modestly Effective

Ob Gyn News ◽  
2007 ◽  
Vol 42 (24) ◽  
pp. 2
Author(s):  
JONATHAN GARDNER
Keyword(s):  
Obesity Drugs

Obesity Drugs' Benefits May Not Outweigh Risks

2007 ◽  
Vol 37 (3) ◽  
pp. 40
Author(s):  
ROBERT FINN
Keyword(s):  
Obesity Drugs

Pair of Novel Obesity Drugs Shows Promise

2009 ◽  
Vol 39 (20) ◽  
pp. 50-51
Author(s):  
HEIDI SPLETE
Keyword(s):  
Obesity Drugs

Obesity Therapy: How and Why?

2020 ◽  
Vol 27 (2) ◽  
pp. 174-186 ◽  
Author(s):  
Sara Paccosi ◽  
Barbara Cresci ◽  
Laura Pala ◽  
Carlo Maria Rotella ◽  
Astrid Parenti
Keyword(s):  
Weight Loss ◽  
Lifestyle Modification ◽  
Herbal Medicines ◽  
The Internet ◽  
Obese Patients ◽  
Self Medication ◽  
Pharmacological Management ◽  
Regulatory Standards ◽  
Meta Analyses ◽  
Obesity Drugs

Background: Obesity represents the second preventable mortality cause worldwide, and is very often associated with type 2 Diabetes Mellitus (T2DM). The first line treatment is lifestyle modification to weight-loss, but for those who fail to achieve the goal or have difficulty in maintaining achieved results, pharmacological treatment is needed. Few drugs are available today, because of their side effects. Objective: We aim to review actual pharmacological management of obese patients, highlighting differences between Food and Drug Administration - and European Medicine Agency-approved molecules, and pointing out self-medications readily obtainable and widely distributed. Methods: Papers on obesity, weight loss, pharmacotherapy, self- medication and diet-aid products were selected using Medline. Research articles, systematic reviews, clinical trials and meta-analyses were screened. Results: Anti-obesity drugs with central mechanisms, such as phentermine and lorcaserin, are available in USA, but not in Europe. Phentermine/topiramate and naltrexone/bupropion combinations are now available, even though the former is still under investigation from EMA. Orlistat, with peripheral mechanisms, represents the only drug approved for weight reduction in adolescents. Liraglutide has been approved at higher dose for obesity. Anti-obesity drugs, readily obtainable from the internet, include crude-drug products and supplements for which there is often a lack of compliance to national regulatory standards. Conclusion: Mechanisms of weight loss drugs include the reduction of energy intake or the increase in energy expenditure and sense of satiety as well as the decrease of hunger or the reduction in calories absorption. Few drugs are approved, and differences exist between USA and Europe. Moreover, herbal medicines and supplements often sold on the internet and widely used by obese patients, present a risk of adverse effects.

Recent Patents on Novel MCH1 Receptor Antagonists as Potential Anti-Obesity Drugs

2014 ◽  
Vol 9 (2) ◽  
pp. 122-140 ◽  
Author(s):  
Katalin Szalai ◽  
Gyula Beke ◽  
Janos Eles ◽  
Tamas Kitka ◽  
Peter Kovacs ◽  
...  
Keyword(s):  
Receptor Antagonists ◽  
Obesity Drugs

scholarly journals Pharmacological treatment of obesity

2006 ◽  
Vol 50 (2) ◽  
pp. 377-389 ◽  
Author(s):  
Marcio C. Mancini ◽  
Alfredo Halpern
Keyword(s):  
Insulin Resistance ◽  
Pharmacological Treatment ◽  
Energy Homeostasis ◽  
Extensive Review ◽  
Obesity Management ◽  
Physiological Mechanisms ◽  
Triggering Factor ◽  
Treatment Of Obesity ◽  
Obesity Drugs ◽  
Cannabinoid Agonist

This review offers an overview of physiological agents, current therapeutics, as well as medications, which have been extensively used and those agents not currently available or non-classically considered anti-obesity drugs. As obesity - particularly that of central distribution - represents an important triggering factor for insulin resistance, its pharmacological treatment is relevant in the context of metabolic syndrome control. The authors present an extensive review on the criteria for anti-obesity management efficacy, on physiological mechanisms that regulate central and/or peripheral energy homeostasis (nutrients, monoamines, and peptides), on beta-phenethylamine pharmacological derivative agents (fenfluramine, dexfenfluramine, phentermine and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrin, phenylpropanolamine), phenylpropanolamine oxytrifluorphenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials - over ten-week long - is also presented for medications used in the management of obesity, as well as data about future medications, such as a the inverse cannabinoid agonist, rimonabant.

Sign in / Sign up

Export Citation Format

Share Document